caa a22 4500 475784340 CHVBK 20180406123653.0 cr unu---uuuuu 170329e20000501xx s 000 0 eng 10.1007/s004310051296 doi (NATIONALLICENCE)springer-10.1007/s004310051296 Treatment and prevention of respiratory syncytial virus infection [Elektronische Daten] [Martin C. J. Kneyber, Henriëtte A. Moll, Ronald de Groot] This review discusses the current knowledge on treatment and prevention of respiratory synctial virus (RSV) infections in children. Unfortunately, an effective therapy is not yet available. The efficacy of corticosteroids and bronchodilators has not yet been adequately documented and the use of ribavirin is only indicated in a highly selected group of high risk patients with T-cell immunodeficiency. The results of studies on the efficacy of vitamin A, interferon and antibiotics showed disappointing results. Vaccination research has produced candidate vaccines such as the recombinant vaccine BBG2Na, a subunit vaccine PFP-2 and cold-passaged-temperature sensitive vaccines. However, phase III efficacy trials in infants, young children and the elderly are still lacking. Passive protection against infections by RSV can be conferred by the use of RSV hyperimmune globulin or by the administration of palivizumab, a monoclonal antibody. However, large costs are involved. In addition, major differences have been reported in the prevalence of RSV lower respiratory tract infections in different countries, regions and even within well-known high-risk populations. Conclusion We suggest the development of local and regional guidelines based on hospitalisation rates in high-risk infants and cost-benefit analysis studies. Springer-Verlag Berlin Heidelberg, 2000 Key words Review, RSV, Treatment, Prevention nationallicence AbbreviationsBPD bronchopulmonary dysplasia nationallicence CHD congenital heart disease nationallicence Cpts cold passaged temperature sensitive nationallicence IFN interferon nationallicence PFP-1 purified fusion protein-1 nationallicence RSV respiratory syncytial virus nationallicence RSVIG respiratory synctial virus immune globulin nationallicence SaO2 oxygen saturation nationallicence Kneyber Martin C. J. Department of Paediatrics, Sophia Children's Hospital Rotterdam, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands e-mail: rdegroot@alkg.azr.nl Tel.: +31-10-4636104; Fax: +31-10-4636449, NL aut Moll Henriëtte A. Department of Paediatrics, Sophia Children's Hospital Rotterdam, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands e-mail: rdegroot@alkg.azr.nl Tel.: +31-10-4636104; Fax: +31-10-4636449, NL aut de Groot Ronald Department of Paediatrics, Sophia Children's Hospital Rotterdam, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands e-mail: rdegroot@alkg.azr.nl Tel.: +31-10-4636104; Fax: +31-10-4636449, NL aut https://doi.org/10.1007/s004310051296 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s004310051296 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kneyber Martin C. J. Department of Paediatrics, Sophia Children's Hospital Rotterdam, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands e-mail: rdegroot@alkg.azr.nl Tel.: +31-10-4636104; Fax: +31-10-4636449, NL aut NATIONALLICENCE 700 1- Moll Henriëtte A. Department of Paediatrics, Sophia Children's Hospital Rotterdam, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands e-mail: rdegroot@alkg.azr.nl Tel.: +31-10-4636104; Fax: +31-10-4636449, NL aut NATIONALLICENCE 700 1- de Groot Ronald Department of Paediatrics, Sophia Children's Hospital Rotterdam, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands e-mail: rdegroot@alkg.azr.nl Tel.: +31-10-4636104; Fax: +31-10-4636449, NL aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer